Advanced HER2-positive gastric cancer: current and future targeted therapies.
about
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.HER-2 overexpression and survival in colorectal cancer: a meta-analysisDual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsHER2 in solid tumors: more than 10 years under the microscope; where are we now?The Therapeutic Challenge of Targeting HER2 in Endometrial CancerHigh mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma.Effects of radiation on the epidermal growth factor receptor pathway in the heartPersonalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesThe progress of targeted therapy in advanced gastric cancerHER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinomaHelicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects.HER2 therapies and gastric cancer: a step forward.HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma.PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.Genetics of gastric cancer.A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.HER-2 Protein Overexpression in Patients with Gastric and Oesophageal Adenocarcinoma at a Tertiary Care Facility in Ghana.Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles.
P2860
Q33429869-D21CD84A-3D19-4C7E-8231-4B6712B027E3Q33979049-E9B2B97C-87BA-48F4-9F05-98FB684F4C99Q34714574-E4DC5612-CDF7-4A91-A725-704D17600385Q35211263-96C00DD8-503D-4E66-8452-A644C1C1DD07Q36064912-D3D72B71-22CD-4A4D-94D1-FD5B4B709863Q36529224-1C7FE75B-4441-4FAB-B629-3DAE88944352Q36980191-CC4F3B6A-ECF8-40B7-BAAD-E168ABE9949FQ37241496-0A572030-CC58-4BE3-83D0-7B0B4A3BC27AQ37427269-3E37A372-E3FC-4ECD-A668-0ABDEC622922Q37632192-34535485-2AB1-49DF-8D21-B038C6970E7BQ38134872-D373FE91-9589-4F3B-951D-0F84FDD13D7FQ38151672-5A01EF87-0FD3-4487-83F8-4ED4F2F8742FQ41839228-4D8F514F-2075-42D9-92FE-13816BFFFD34Q47838777-7C8221F1-8B83-44E6-8EBC-981EB5A94CBCQ48327644-53D53FC3-83CA-4CCB-8308-1D65C351F90EQ50761028-C8FFF1E9-F240-43BA-A0A5-56DE34773FDDQ51219045-BAFD92A0-AB8A-41B4-BB19-32273C2FEF22Q52597562-C26541B1-1C56-4F5D-8A51-CEBC09116FEAQ55030120-E1AAE17C-36DC-4072-9C80-D67682945808Q55210424-CC930C2A-F3B0-414A-ACFE-FDA0D4CC5848
P2860
Advanced HER2-positive gastric cancer: current and future targeted therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advanced HER2-positive gastric cancer: current and future targeted therapies.
@en
type
label
Advanced HER2-positive gastric cancer: current and future targeted therapies.
@en
prefLabel
Advanced HER2-positive gastric cancer: current and future targeted therapies.
@en
P1476
Advanced HER2-positive gastric cancer: current and future targeted therapies.
@en
P2093
Antonio Antón
Roberto A Pazo Cid
P304
P356
10.1016/J.CRITREVONC.2012.08.008
P577
2012-09-26T00:00:00Z